Korro Bio (KRRO) Enterprise Value (2018 - 2026)
Korro Bio's (KRRO) quarterly Enterprise Value came in at -$114.0 million in Q1 2026, up 0.86% YoY from -$113.0 million in Q1 2025, and down 51.64% on a QoQ basis from -$75.2 million in Q4 2025.
Korro Bio (KRRO) Enterprise Value (2018 - 2026) Analysis & Trends
Korro Bio (KRRO) has 9 years of Enterprise Value data on file, last reported at -$114.0 million in Q1 2026.
- Quarterly Enterprise Value rose 0.86% year-over-year to -$114.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$114.0 million (up 0.86% YoY) and the FY2025 annual result came in at -$75.2 million, up 40.4% from the prior year.
- Enterprise Value fell to -$114.0 million in Q1 2026, from -$75.2 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$36.9 million in Q4 2022 to a low of -$169.8 million in Q4 2023.
- A 5-year average of -$102.7 million and a median of -$111.0 million in 2022 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2022 — Enterprise Value soared 71.74% — and 2023, when it sank 359.62%.
- Tracing KRRO's Enterprise Value over 5 years: stood at -$36.9 million in 2022, then plunged by 359.62% to -$169.8 million in 2023, then gained by 25.72% to -$126.1 million in 2024, then soared by 40.4% to -$75.2 million in 2025, then plunged by 51.64% to -$114.0 million in 2026.
- The last three Enterprise Value figures came in at -$114.0 million (Q1 2026), -$75.2 million (Q4 2025), and -$92.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Korro Bio | 228.60 Mn | 113.56 Mn | - | -115.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -115.04 Mn |
| Mar 31, 2026 | -113.97 Mn |
| Dec 31, 2025 | -75.16 Mn |
| Sep 30, 2025 | -92.48 Mn |
| Jun 30, 2025 | -96.36 Mn |
| Mar 31, 2025 | -114.95 Mn |
| Dec 31, 2024 | -126.10 Mn |
| Sep 30, 2024 | -137.00 Mn |
| Jun 30, 2024 | -157.43 Mn |
| Mar 31, 2024 | -142.35 Mn |
| Dec 31, 2023 | -169.75 Mn |
| Sep 30, 2023 | -41.72 Mn |
| Jun 30, 2023 | -46.48 Mn |
| Mar 31, 2023 | -66.65 Mn |
| Dec 31, 2022 | -36.93 Mn |
| Sep 30, 2022 | -99.35 Mn |
| Jun 30, 2022 | -111.02 Mn |
| Mar 31, 2022 | -117.36 Mn |
| Dec 31, 2021 | -130.71 Mn |
| Sep 30, 2021 | -148.07 Mn |